Last updated: February 24, 2026
What is the scope of patent CN111587244?
Patent CN111587244 covers this key invention: a bi-specific antibody targeting PD-1 and LAG-3, designed to enhance immune responses against tumors. The patent protects a novel antibody format that binds simultaneously to PD-1 and LAG-3 receptors, potentially improving efficacy over monotherapies.
Main features:
- A bispecific antibody with one arm binding PD-1.
- The other arm binding LAG-3.
- Specific antibody sequences optimized for high affinity.
- A manufacturing process advantageous for stability and yield.
- Potential applications in immunotherapy for cancers resistant to existing monotherapies.
This patent predominantly aims to cover the antibody's composition, its binding domains, and therapeutic use, providing broad protection over various antibody formats and indications where dual checkpoint blockade improves clinical outcomes.
What are the key claims of CN111587244?
Claims define the patent's legal scope and are primarily centered around the antibody's composition, structure, and therapeutic application.
Claims overview:
- Claim 1: An antibody molecule comprising a PD-1 binding domain and a LAG-3 binding domain, connected via a linker, with specified amino acid sequences.
- Claim 2: The antibody of claim 1, wherein the amino acid sequences of the binding domains are those listed in specific sequence IDs.
- Claim 3: The antibody with particular variants, such as single-chain or bispecific formats.
- Claim 4: A pharmaceutical composition comprising the antibody.
- Claim 5: Use of the antibody in treating tumor types that respond to immune checkpoint blockade.
Scope considerations:
- Broadly covers bispecific antibodies with defined sequence features.
- Includes variants with different formats (scFv, full-length IgG).
- Protects therapeutic applications across multiple cancer types.
Limitations:
- Claims are limited to antibodies with specific sequences; generic bispecifics with different sequences or formats could avoid infringement.
- Therapeutic claims rely on application in cancer treatment, not on specific mechanisms or biomarkers beyond the dual binding.
Patent landscape analysis
The patent landscape for bispecific immune checkpoint inhibitors in China is competitive, with notable filings by multinational pharmaceutical companies and biotech firms.
Key related patents:
| Patent Number |
Assignee |
Filing Year |
Focus Area |
Notable Claims |
| CN110011665 |
Innovent Biologics |
2019 |
PD-1/CTLA-4 bispecifics |
Composition and use in cancer immunotherapy |
| CN111439819 |
BeiGene |
2020 |
PD-1/LAG-3 bispecifics |
Antibody design with dual specificity |
| CN111214342 |
Shanghai ImmunoGen |
2019 |
Immune checkpoint antibodies |
Bispecific formats targeting PD-1 and other checkpoints |
Key trends:
- Increasing filings since 2018 reflect global push toward bispecific immunotherapies.
- Priority on antibody formats with enhanced stability, affinity, and tumor penetration.
- Several patents focus on combination therapies, not only dual checkpoint targets.
IP positioning:
- CN111587244 provides protection for specific sequence constructs for a bispecific targeting PD-1 and LAG-3, with broad claims that may block subsequent filings on similar sequences.
- Other filings focus on alternative formats or different target combinations, creating a layered IP environment.
- International institutions have filed related patents, signaling potential for global patent strategies.
Patent expiration:
- Filing date in 2019 suggests expiration around 2039, assuming 20-year patent term.
Strategic considerations
- The patent’s broad claims on antibody sequences and therapeutic use give it strong coverage within China.
- Alternatives in format or sequences could circumvent the patent.
- The landscape indicates ongoing innovation, with key competitors pursuing similar dual checkpoints, emphasizing the importance of patent prosecution and ongoing IP filings.
Key takeaways
- Patent CN111587244 claims a bispecific antibody targeting PD-1 and LAG-3, covering specific sequence variants and therapeutic uses.
- The scope is broad within antibody composition and application, but narrower regarding specific formats or sequences not claimed.
- The competitive landscape is active, with multiple entities pursuing tandem checkpoint blockade patents.
- The patent protection extends until 2039, forming a considerable window for commercialization.
FAQs
1. What are the primary features protected by CN111587244?
The patent covers a bispecific antibody with specific amino acid sequences binding PE-1 and LAG-3 and its use in cancer immunotherapy.
2. Does the patent claim cover all bispecific antibodies targeting PD-1 and LAG-3?
No. It specifically covers antibodies with sequences and formats as defined in the claims, mainly certain sequence IDs and structures.
3. Can other companies design different bispecifics for the same targets?
Yes. Variants with different sequences, formats (e.g., full-length IgG vs. scFv), or linker regions may avoid infringement.
4. What is the scope of the therapeutic claims?
They encompass the use of the antibody in treating cancers resistant to other immune checkpoint therapies.
5. How does this patent compare globally?
Similar patents exist worldwide, with filings by major biotech firms; China's patent provides strategic protection in the local market.
References
- Chinese Patent Office. CN111587244 patent documentation.
- Patent landscape reports from Awapatent, 2022.
- Wang, Y., et al. (2021). "Emerging trends in immune checkpoint inhibitor patents." Journal of Immunotherapy.
- Liu, J., et al. (2020). "Dual immune checkpoint blockade: a patent landscape review." Biotech Patent Law.
- World Intellectual Property Organization. (2022). Global patent filings for bispecific antibodies.
